Gastroenterology

In 455 subjects, the eradication rate of RHB-105 was superior to that of the active comparator (83.8% vs 57.7%, p< 0.0001).

Among patients with UC, elderly individuals (age >65 years old), females, and Caucasians were more likely to be affected by psychiatric illness.

In a late breaking clinical trial at ACG 2019, investigators say AK002 shows promise in treating patients with EGID.

Compared to hospitalized patients with ulcerative colitis but without C diff infection, hospitalized patients with ulcerative colitis and C diff experienced increased mortality.

Investigators present data from a new study showing that RHB-104 can effectively combat MAP infections for patients with moderately to severely active Crohn’s disease.

Brian Feagan, MD, shares takeaways from his ACG presentation of phase 2 data on risankizumab for the treatment of Crohn's disease.

During the annual ACG meeting, Roberto Simons-Linares, MD explained how cannabis use impacts the fluids of patients suffering from acute necrotizing pancreatitis.

At ACG 2019, Ikuo Hirano, MD, FACG, presents phase 3 results of budesonide oral suspension for the treatment of eosinophilic esophagitis.

Diagnostic procedures of the large intestine were the most common claims within those against gastroenterologists, making up 26% of all closed claims.

The study drug at 600 mg was associated with significant improvements in Crohn’s Disease Activity Index scores as early as Week 2.

From baseline to 12 weeks, all participants demonstrated a significant reduction in total percentage of abnormal bowel movements, overall IBS Symptom Severity Score, abdominal pain and bloating severity, and an improvement in health-related quality of life.

Investigators observed clinical response in 15 patients (83%) who underwent the second IV reinduction. Three patients (17%) did not respond and were taken off the therapy.

In a retrospective study presented at the annual ACG meeting, investigators examine sex and ethnicity data involving linkage to care for hepatitis C virus patients.

In data presented during the annual ACG meeting, investigators show vedolizumab can be safe and effective for treating pediatric patients with IBD who have failed anti-TNF therapy.

In a new poster presented at the annual ACG meeting in San Antonio, researchers compare morbidity and mortality for ulcerative colitis patients with or without C. diff or CMV infections.

A new study presented at CHEST 2019 shows pulmonologists and ILD specialists will either reduce or temporarily interrupt antifibrotic care, depending on the form of adverse events a patient is experiencing.

Ustekinumab (Stelara) has received approval from the US Food and Drug Administration for the treatment of moderate to severely active ulcerative colitis in adults.

Data from a 961-patient study shows that ustekinumab can induce and maintain remission for patients with moderate-to-severe ulcerative colitis.

Investigators discover vedolizumab induces endoscopic remission in 33% of Crohn’s disease patients and histologic remission in 66% of patients after 52 weeks.

Recent measures in the UK has led to a drop in IBD patients using corticosteroids to excess.

In a new trial, investigators test whether continuing or discontinuing ADA is more beneficial.

The largest improvements for patients taking ustekinumab occurred following treatment every 8 weeks.

The AGA-approved guidelines call for a variety of different testing to better diagnose IBS-D in adults.

In the updated guidelines, investigators suggest direct-acting antivirals as the preferred treatment for hepatitis C viral infections in chronic kidney disease patients.

The FDA-approved drug targets IBS-C patients by increasing bowel movements, while lowering abdominal pain.